- Home
- CRVO vs EDAP Comparison
CRVO vs EDAP Comparison
Compare CRVO & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- EDAP
- Stock Information
- Founded
- CRVO 2001
- EDAP 1979
- Country
- CRVO United States
- EDAP France
- Employees
- CRVO N/A
- EDAP N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CRVO Health Care
- EDAP Health Care
- Exchange
- CRVO Nasdaq
- EDAP Nasdaq
- Market Cap
- CRVO 95.4M
- EDAP 88.7M
- IPO Year
- CRVO N/A
- EDAP 1997
- Fundamental
- Price
- CRVO $8.91
- EDAP $2.40
- Analyst Decision
- CRVO Strong Buy
- EDAP Strong Buy
- Analyst Count
- CRVO 8
- EDAP 1
- Target Price
- CRVO $25.43
- EDAP $19.00
- AVG Volume (30 Days)
- CRVO 13.3M
- EDAP 74.4K
- Earning Date
- CRVO 03-17-2025
- EDAP 05-15-2025
- Dividend Yield
- CRVO N/A
- EDAP N/A
- EPS Growth
- CRVO N/A
- EDAP N/A
- EPS
- CRVO N/A
- EDAP N/A
- Revenue
- CRVO $9,737,974.00
- EDAP $70,722,730.00
- Revenue This Year
- CRVO N/A
- EDAP $6.96
- Revenue Next Year
- CRVO N/A
- EDAP $15.53
- P/E Ratio
- CRVO N/A
- EDAP N/A
- Revenue Growth
- CRVO 36.29
- EDAP 12.17
- 52 Week Low
- CRVO $1.80
- EDAP $2.00
- 52 Week High
- CRVO $25.92
- EDAP $8.50
- Technical
- Relative Strength Index (RSI)
- CRVO 63.30
- EDAP 32.33
- Support Level
- CRVO $8.53
- EDAP $2.06
- Resistance Level
- CRVO $16.94
- EDAP $2.42
- Average True Range (ATR)
- CRVO 2.01
- EDAP 0.17
- MACD
- CRVO 0.66
- EDAP -0.03
- Stochastic Oscillator
- CRVO 50.33
- EDAP 8.47
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.